In the UK each year, ovarian cancer is diagnosed in over 6500 women and causes approximately 4400 deaths. Many women present with advanced disease with little prospect of cure. The 5-year survival rate for advanced ovarian cancer between 2005 and 2009 was 43%.
The current standard of care consists of the combination of radical surgery and platinum-based chemotherapy. Although key advances in surgical and chemotherapeutic strategies have led to small improvements in outcome, there still remains a significant risk of recurrence and resistance to therapy and a need to improve current treatment options.
This paper discusses the various available treatment options and areas where further research is needed.
This Scientific Impact Paper was developed prior to the emergence of the COVID-19 coronavirus.
This is the second edition of this Scientific Impact Paper, which was originally published in 2008 under the same title.
Please note that the Scientific Advisory Committee regularly assesses the need to update. Further information on this review is available on request.
Developer declaration of interests
Available on request